Skip to content
value.today
Karyopharm Therapeutics Inc. logo

Karyopharm Therapeutics Inc.

KPTI
$20 Mmarket cap on Oct 30, 2026-79.2% since Jan 2024
Compare
World rank
#24,359
Revenue
$146 M
For year ending December-2025
Net income
$-196 M
-134.2% margin
SEC filing
Employees
442
As on 2021
value.today research

Karyopharm Therapeutics Inc. in brief

Karyopharm Therapeutics Inc. is a listed company in the Biotechnology industry, based in Newton, Massachusetts, USA. Its market value was $20 M on 30 October 2026, which makes it the 24,359th largest listed company in the world and the 4,160th largest in the USA on this site. In the year to December 2025 it had sales of $146 M and a net loss of $196 M. It employs about 442 people and Richard A. Paulson is its chief executive. Its largest product and service lines by sales in 2025 were License and Other Revenue (21%). Its shares trade under the symbol KPTI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics is an Innovation Driven Pharmaceutical company. It is focused on the discovery, development and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases. The headquarters is in USA.

Karyopharm Therapeutics Inc. timeline

3 events, 2010–2021
  1. 2010
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2013
  4. 🔔
    · approximate
    Initial public offering on Nasdaq
  5. 2021
  6. 💰
    Record revenue of $210 million
    FY2021, the highest of the 8 years on record.

Events of Karyopharm Therapeutics Inc. from SEC EDGAR, the company record and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$312 M$625 M$937 M$1.2 B2020202120222023202420252026

World rank over time

▼ down 17,367 places since 2020
2020-01-01: #7019#7,01920202021-01-01: #7510#7,51020212022-01-07: #13136#13,13620222022-12-25: #17754#17,75420222023-07-30: #17907#17,90720232024-01-05: #21646#21,64620242026-03-08: #9298#9,29820262026-08-01: #19668#19,66820262026-10-30: #24386#24,3862026

Rank in USA: #1,960 (Jan 2020) · #2,060 (Jan 2021) · #3,217 (Jan 2022) · #3,627 (Dec 2022) · #3,584 (Jul 2023) · #3,722 (Jan 2024) · #1,792 (Mar 2026) · #3,763 (Aug 2026) · #4,163 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.1×
Price / book
—
Free cash flow yield
-377.6%
Net margin (TTM)
-153.3%
Operating margin
-62.1%
Return on equity
—
Liabilities / assets
370.2%
Net debt
$-21M
Revenue growth
+0.6%
R&D / revenue
86.0%
Revenue per employee
$330 K
Profit per employee
$-444 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $30M, net income $-178M$30MFY18Fiscal year ending Dec 2019: revenue $41M, net income $-200M$41MFY19Fiscal year ending Dec 2020: revenue $108M, net income $-196M$108MFY20Fiscal year ending Dec 2021: revenue $210M, net income $-124M$210MFY21Fiscal year ending Dec 2022: revenue $157M, net income $-165M$157MFY22Fiscal year ending Dec 2023: revenue $146M, net income $-143M$146MFY23Fiscal year ending Dec 2024: revenue $145M, net income $-76M$145MFY24Fiscal year ending Dec 2025: revenue $146M, net income $-196M$146MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$146M+0.6%$-91M$-196M-134.2%
Dec 2024$145M-0.5%$-119M$-76M-52.6%
Dec 2023$146M-7.0%$-130M$-143M-98.0%
Dec 2022$157M-25.1%$-142M$-165M-105.2%
Dec 2021$210M+94.1%$-98M$-124M-59.1%
Dec 2020$108M+164.3%$-172M$-196M-181.6%
Dec 2019$41M+34.8%$-189M$-200M-488.1%
Dec 2018$30M—$-180M$-178M-588.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-75M$0M$-75M$-17.93—
Dec 2024$-127M$0M$-128M$-14.00—
Dec 2023$-93M$0M$-93M$-18.79—
Dec 2022$-150M$0M$-150M$-2.02—
Dec 2021$-107M$0M$-107M$-1.65—
Dec 2020$-160M$0M$-160M$-2.72—
Dec 2019$-191M$0M$-191M$-3.22—
Dec 2018$-159M$2M$-161M$-3.14—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$147M
Net income, trailing 12 months
$-225M
RevenueNet income
Three months to Sep 2024: revenue $39M, net income $-32M$39MSep ’24Three months to Dec 2024 (from the annual report): revenue $31M, net income $-31M$31MDec ’24Three months to Mar 2025: revenue $30M, net income $-23M$30MMar ’25Three months to Jun 2025: revenue $38M, net income $-37M$38MJun ’25Three months to Sep 2025: revenue $44M, net income $-33M$44MSep ’25Three months to Dec 2025 (from the annual report): revenue $34M, net income $-102M$34MDec ’25Three months to Mar 2026: revenue $35M, net income $-22M$35MMar ’26Three months to Jun 2026: revenue $33M, net income $-67M$33MJun ’26

Latest quarter to Jun 2026: revenue $33M (-11.9% on a year earlier), net income $-67M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Karyopharm Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$146 M
Operating income
$-91 M
Net income
$-196 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$108 M
Total liabilities
$401 M
Total equity
$-293 M

As of December-2025

Top 92 institutional investors in Karyopharm Therapeutics Inc.#

As of Sep 30, 2026
92 institutions held 17.3 M shares (about 76.4% of the shares outstanding) on Sep 30, 2026. The ten largest hold 46.7%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Karyopharm Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Adage Capital Partners GP, L.L.C.1,997,692+476,370 (+31.31%)8.81%$2 MNov 16, 2026
2BlackRock, Inc.1,521,918+103,119 (+7.27%)6.71%$2 MNov 13, 2026
3Acorn Capital Advisors, LLC1,222,019-296,094 (-19.50%)5.39%$1 MNov 16, 2026
4Catalio Capital Management, LP976,191+35,336 (+3.76%)4.30%$1 MNov 16, 2026
5UBS Group AG963,891+610,346 (+172.64%)4.25%$1 MNov 10, 2026
6Vanguard Capital Management LLC940,813-18,166 (-1.89%)4.15%$1 MNov 13, 2026
7AQR Capital Management LLC931,658New4.11%$1 MNov 16, 2026
8Avidity Partners Management LP884,900-39,587 (-4.28%)3.90%$1 MNov 16, 2026
9Acadian Asset Management LLC617,904+318,907 (+106.66%)2.72%$1 MNov 9, 2026
10Strs Ohio542,500New2.39%$1 MOct 30, 2026
11Geode Capital Management, LLC458,521-72,710 (-13.69%)2.02%$1 MNov 6, 2026
12Morgan Stanley385,745+183,239 (+90.49%)1.70%$0 MNov 13, 2026
13State Street Corp369,341+43,350 (+13.30%)1.63%$0 MNov 12, 2026
14Brevan Howard Capital Management LP352,637+42,820 (+13.82%)1.55%$0 MNov 16, 2026
15Royal Bank Of Canada310,728+250,298 (+414.19%)1.37%$0 MNov 16, 2026
16Davidson Kempner Capital Management LP300,0000 (0.00%)1.32%$0 MNov 16, 2026
17Bank Of America Corp /de/278,982+229,058 (+458.81%)1.23%$0 MNov 16, 2026
18Two Sigma Investments, LP273,870-421,394 (-60.61%)1.21%$0 MNov 16, 2026
19Context Capital Management, LLC263,696New1.16%$0 MNov 4, 2026
20Goldman Sachs Group Inc256,190-1,168,468 (-82.02%)1.13%$0 MNov 16, 2026
21Jpmorgan Chase & Co250,611+43,002 (+20.71%)1.10%$0 MNov 12, 2026
22FMR LLC240,312+231,376 (+2589.26%)1.06%$0 MNov 10, 2026
23Jane Street Group, LLC195,300+162,127 (+488.73%)0.86%$0 MNov 12, 2026
24Susquehanna International Group, LLP191,231New0.84%$0 MNov 16, 2026
25Caption Management, LLC185,745New0.82%$0 MNov 16, 2026
Show all 92: investors 26 to 92
Institutional investors 26 to 92 in Karyopharm Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Prudential Financial Inc172,610New0.76%$0 MNov 16, 2026
27Northern Trust Corp159,937-69 (-0.04%)0.71%$0 MNov 16, 2026
28Citadel Advisors LLC146,782+94,713 (+181.90%)0.65%$0 MNov 16, 2026
29Invesco Ltd.136,524+46,220 (+51.18%)0.60%$0 MNov 12, 2026
30Vanguard Portfolio Management LLC135,902+1,084 (+0.80%)0.60%$0 MNov 13, 2026
31Boxer Capital Management, LLC127,536-175,000 (-57.84%)0.56%$0 MNov 16, 2026
32Vanguard Fiduciary Trust Co114,068-31,333 (-21.55%)0.50%$0 MNov 13, 2026
33Virtu Financial LLC110,484+99,756 (+929.87%)0.49%$0 MNov 17, 2026
34D. E. Shaw & Co., Inc.95,740New0.42%$0 MNov 16, 2026
35Quadrature Capital Ltd87,086+76,790 (+745.82%)0.38%$0 MNov 13, 2026
36Panagora Asset Management Inc81,102New0.36%$0 MNov 12, 2026
37BNP Paribas Financial Markets73,605-114,433 (-60.86%)0.32%$0 MNov 12, 2026
38BML Capital Management, LLC71,839New0.32%$0 MNov 6, 2026
39Bridgeway Capital Management, LLC71,483-390 (-0.54%)0.32%$0 MNov 16, 2026
40Simplex Trading, LLC69,837+45,751 (+189.95%)0.31%$0 MNov 4, 2026
41Nuveen, LLC65,578+27,710 (+73.18%)0.29%$0 MNov 10, 2026
42Bank of New York Mellon Corp57,2620 (0.00%)0.25%$0 MNov 5, 2026
43Group One Trading LLC51,174New0.23%$0 MNov 10, 2026
44Charles Schwab Investment Management Inc48,520-13,423 (-21.67%)0.21%$0 MNov 16, 2026
45Citigroup Inc47,191+9,274 (+24.46%)0.21%$0 MNov 4, 2026
46Millennium Management LLC42,888-262,788 (-85.97%)0.19%$0 MNov 16, 2026
47Marshall Wace, LLP39,400-89,051 (-69.33%)0.17%$0 MNov 13, 2026
48Intellus Advisors LLC38,232New0.17%$0 MNov 13, 2026
49China Universal Asset Management Co., Ltd.36,000+11,000 (+44.00%)0.16%$0 MOct 28, 2026
50Silverback Asset Management LLC35,000+5,000 (+16.67%)0.15%$0 MNov 16, 2026
51Nomura Asset Management International Inc.33,3330 (0.00%)0.15%$0 MNov 16, 2026
52Rhumbline Advisers30,772+7,305 (+31.13%)0.14%$0 MNov 10, 2026
53Barclays PLC28,739-137,165 (-82.68%)0.13%$0 MNov 6, 2026
54Price T Rowe Associates Inc /MD/27,2250 (0.00%)0.12%$0 MNov 16, 2026
55Empowered Funds, LLC21,610New0.10%$0 MNov 13, 2026
56SEI Investments Co21,436+6,353 (+42.12%)0.09%$0 MNov 10, 2026
57Toronto Dominion Bank20,000-10,930 (-35.34%)0.09%$0 MNov 16, 2026
58Deutsche Bank AG\17,029-2,396 (-12.33%)0.08%$0 MNov 6, 2026
59StoneX Group Inc.17,019New0.07%$0 MNov 3, 2026
60HSBC Holdings PLC13,7500 (0.00%)0.06%$0 MNov 16, 2026
61MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.9,640+469 (+5.11%)0.04%$0 MNov 16, 2026
62Vanguard Global Advisers, LLC8,244+37 (+0.45%)0.04%$0 MNov 13, 2026
63Russell Investments Group, Ltd.6,789+5,197 (+326.44%)0.03%$0 MNov 6, 2026
64Police & Firemen's Retirement System of New Jersey5,8740 (0.00%)0.03%$0 MNov 9, 2026
65TD Waterhouse Canada Inc.5,7070 (0.00%)0.03%$0 MOct 16, 2026
66New York State Common Retirement Fund5,6000 (0.00%)0.02%$0 MNov 17, 2026
67Tower Research Capital LLC (TRC)4,607+3,348 (+265.93%)0.02%$0 MNov 16, 2026
68Wells Fargo & Company/mn4,196-12,707 (-75.18%)0.02%$0 MNov 16, 2026
69PNC Financial Services Group, Inc.3,974New0.02%$0 MNov 6, 2026
70Arax Advisory Partners2,451New0.01%$0 MNov 12, 2026
71Global Retirement Partners, LLC2,155New0.01%$0 MNov 10, 2026
72Legal & General Group Plc1,9350 (0.00%)0.01%$0 MNov 16, 2026
73Ameritas Investment Partners, Inc.1,8080 (0.00%)0.01%$0 MNov 13, 2026
74Harbour Investments, Inc.1,285+1,000 (+350.88%)0.01%$0 MNov 9, 2026
75GAMMA Investing LLC865New0.00%$0 MOct 8, 2026
76Owl Creek Wealth Partners LLC685New0.00%$0 MOct 20, 2026
77Osaic Holdings, Inc.4020 (0.00%)0.00%$0 MNov 12, 2026
78Sterling Capital Management LLC340-12 (-3.41%)0.00%$0 MOct 22, 2026
79Huntington National Bank278New0.00%$0 MNov 10, 2026
80California State Teachers Retirement System2740 (0.00%)0.00%$0 MNov 13, 2026
81Caitong International Asset Management Co., Ltd249+235 (+1678.57%)0.00%$0 MOct 29, 2026
82Cantor Fitzgerald, L. P.173New0.00%$0 MNov 16, 2026
83Quent Capital, LLC1660 (0.00%)0.00%$0 MNov 13, 2026
84Allworth Financial LP115+89 (+342.31%)0.00%$0 MNov 17, 2026
85MB, Levis & Associates, LLC1000 (0.00%)0.00%$0 MOct 16, 2026
86SBI Securities Co., Ltd.69+2 (+2.99%)0.00%$0 MOct 22, 2026
87Activest Wealth Management660 (0.00%)0.00%$0 MOct 15, 2026
88Farther Finance Advisors, LLC66New0.00%$0 MOct 8, 2026
89EverSource Wealth Advisors, LLC15New0.00%$0 MNov 4, 2026
90IFP Advisors, Inc7New0.00%$0 MOct 16, 2026
91West Branch Capital LLC30 (0.00%)0.00%$0 MOct 20, 2026
92PlanVest Financial, Inc10 (0.00%)0.00%$0 MNov 9, 2026

Mutual funds holding Karyopharm Therapeutics Inc.#

64 funds hold shares worth $29 M (about 13.2% of the company). Since their previous reports 56 added shares and 1 sold, buying $8 M net.
Mutual funds holding Karyopharm Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.677,729$7 M3.0%<0.01%+33%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors490,317$5 M2.2%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.435,070$4 M1.9%0.04%−50%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.263,084$3 M1.2%<0.01%+22%Jun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Value Fund, Inc.T. Rowe Price Associates, Inc.447,624$2 M—0.02%no changeJun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors153,539$2 M0.68%0.01%newJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC94,581$1 M0.42%<0.01%+5.0%May 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors81,441$1 M0.36%<0.01%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors66,938$1 M0.30%0.04%+57%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC216,009$0 M0.95%<0.01%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC37,232$0 M0.16%<0.01%newJun 30, 2026
🇺🇸 Nomura Healthcare FundDelaware Management Company33,333$0 M0.15%0.04%no changeJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC34,152$0 M0.15%<0.01%+13%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC28,115$0 M0.12%<0.01%+18%May 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC23,571$0 M0.10%0.01%newJun 30, 2026
🇺🇸 Ultra-Small Company Market FundBridgeway Capital Management, LLC22,000$0 M0.10%0.15%no changeJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC21,052$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation14,900$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.10,886$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.10,410$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Diversified Equity Alpha Master PortfolioBlackRock Fund Advisors10,259$0 M0.05%<0.01%+595%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.10,021$0 M0.04%<0.01%no changeJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.48,520$0 M0.21%<0.01%newJul 31, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC10,033$0 M0.04%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.8,145$0 M0.04%<0.01%+48%Jun 30, 2026
🇺🇸 VIP Disciplined Small Cap PortfolioFidelity Management & Research Company LLC8,052$0 M0.04%0.01%newJun 30, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC6,815$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.6,800$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Invesco RAFI US 1500 Small-Mid ETFInvesco Capital Management LLC32,185$0 M0.14%<0.01%+92%Jul 31, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC5,758$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC5,505$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC26,676$0 M0.12%<0.01%newJul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC4,517$0 M0.02%0.02%+50%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC4,357$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC4,315$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS4,306$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC3,530$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC3,530$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC3,167$0 M0.01%<0.01%+116%Jun 30, 2026
🇺🇸 BlackRock Advantage SMID Cap V.I. FundBlackRock Advisors, LLC3,139$0 M0.01%0.02%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.3,116$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.3,002$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC2,805$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC2,638$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.13,400$0 M0.06%<0.01%no changeJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC2,564$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC2,459$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC9,500$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management1,808$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC1,592$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC1,464$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC1,138$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC942$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC4,151$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC676$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC645$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.503$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC2,332$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.2,258$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC407$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS1,734$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS1,561$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,383$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC226$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC126$0 M<0.01%<0.01%+30%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 65 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Karyopharm Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$350 K
21 sales, 7 insiders
Net, 12 months
-$350 K
open market only
Insiders on file
33
since
-$1.5 M$0Nov 2023: bought $0 (0 trades), sold $3 K (1 trades)Nov 23Dec 2023: bought $0 (0 trades), sold $3 K (1 trades)Jan 2024: bought $0 (0 trades), sold $3 K (1 trades)Feb 2024: bought $0 (0 trades), sold $234 K (11 trades)Mar 2024: bought $0 (0 trades), sold $60 K (7 trades)MarApr 2024: bought $0 (0 trades), sold $13 K (2 trades)May 2024: bought $0 (0 trades), sold $198 K (3 trades)Jun 2024: bought $0 (0 trades), sold $1.5 M (12 trades)Jul 2024: bought $0 (0 trades), sold $6 K (2 trades)JulAug 2024: bought $0 (0 trades), sold $3 K (1 trades)Sep 2024: bought $0 (0 trades), sold $14 K (4 trades)Oct 2024: bought $0 (0 trades), sold $3 K (1 trades)Nov 2024: bought $0 (0 trades), sold $3 K (1 trades)NovDec 2024: bought $0 (0 trades), sold $3 K (1 trades)Jan 2025: bought $0 (0 trades), sold $3 K (1 trades)Feb 2025: bought $0 (0 trades), sold $6 K (2 trades)Mar 2025: bought $0 (0 trades), sold $161 K (6 trades)MarApr 2025: bought $0 (0 trades), sold $4 K (2 trades)May 2025: bought $0 (0 trades), sold $2 K (1 trades)Jul 2025: bought $0 (0 trades), sold $2 K (2 trades)Sep 2025: bought $0 (0 trades), sold $17 K (7 trades)SepOct 2025: bought $0 (0 trades), sold $2 K (1 trades)Jan 2026: bought $0 (0 trades), sold $2 K (2 trades)Feb 2026: bought $0 (0 trades), sold $14 K (2 trades)Mar 2026: bought $0 (0 trades), sold $294 K (6 trades)MarApr 2026: bought $0 (0 trades), sold $4 K (1 trades)May 2026: bought $0 (0 trades), sold $35 K (6 trades)Jul 2026: bought $0 (0 trades), sold $1 K (1 trades)Sep 2026: bought $0 (0 trades), sold $38 (1 trades)SepOct 2026: bought $0 (0 trades), sold $450 (2 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Karyopharm Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Kristin AbateChief Accounting OfficerSell-4,788$0.344—18,616Form 4
filed Kristin AbateChief Accounting OfficerSell-378$1.190$45023,404Form 4
filed Kristin AbateChief Accounting OfficerSell-19$2.020$3823,782Form 4
filed Stuart PoultonEVP, Chief Development OfficerSell-189$7.100$1 K94,632Form 4
filed Barry E. GreeneDirectorGrant or award+15,508——16,415Form 4
filed Deepika PakianathanDirectorGrant or award+15,508——15,508Form 4
filed Chen SchorDirectorGrant or award+15,508——15,508Form 4
filed Zhen SuDirectorGrant or award+15,508——15,508Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Karyopharm Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
8.2 M
45.0% of shares · 1.09 days to cover
Shares sold short, last 24 reportsAll stocks →

Bankruptcy filing: (8-K)

Trading halts

  • 2026-11-02 12:07 UTC, code T3, resumed 12:40 UTC
  • 2026-07-30 20:01 UTC, code T3, resumed 20:35 UTC
  • 2026-03-24 10:56 UTC, code T3, resumed 11:30 UTC
  • 2025-08-15 16:32 UTC, code LUDP, resumed 16:37 UTC
  • 2025-02-26 00:50 UTC, code T3, resumed 14:00 UTC

Fails to deliver

  • : 362,517 shares at $0.88
  • : 766,706 shares at $0.83
  • : 2,661 shares at $0.48
  • : 17,824 shares at $0.48
  • : 126,452 shares at $0.52

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Karyopharm Therapeutics Inc. scorecard#

Passes 5 of the 18 checks that could be worked out: strongest in growth (2 of 6), weakest in valuation (1 of 4). Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median0.1×Price to sales 0.1× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth2 of 6
    • ✓Revenue grew in the newest year0.6%Revenue up 0.6% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-2.4%-2.4% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-2.4%-2.4% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year-17.93 vs -14.00Diluted EPS -17.93 in fiscal 2025 against -14.00 the year before (report's currency).
    • ✓Net income higher than five years earlier-$196 M-$196 M in fiscal 2025 against -$196 M in 2020.
    • ✗Revenue rose in at least four of the last five years2 of 5Revenue rose in 2 of the five years to fiscal 2025.
  • Profitability1 of 4
    • ✗Profitable in the newest year-$196 MNet income -$196 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-62.1%-62.1% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-62.1%-62.1% in fiscal 2025 against -90.5% in 2022.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities1.1×Current ratio 1.12 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-23.98Z-score -23.98 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year37.5%Diluted shares up 37.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Karyopharm Therapeutics Inc.'s statements, beside the median of Biotechnology.

Karyopharm Therapeutics Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-62.1%-60.5%
Net margin-134.2%-68.9%
Revenue growth, 3 years a year-2.4%12.9%
Revenue growth0.6%15.8%
Free cash flow margin-51.6%-61.5%

2of 7on the Piotroski tests of financial strength

  • Net loss of $196 million, the 14th loss-making year in a row.
  • Free cash flow was negative: -$75 million.
  • The share count rose 37.5% in the year.
  • Shareholders' equity is negative: -$293 million.

Karyopharm Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Karyopharm Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue14614514615721010841301.60.2
Research and development12614313914916115112216110787
Selling, general and administrative1051151321451441261054925—
General and administrative———————492524
Operating expenses237265276299308280230210132111
Operating income−91−119−130−142−98−172−189−180−131−111
Interest and finance income2.87.4112.40.62.85.44.01.71.3
Interest expense and finance costs463724252627162.5——
Other non-operating income (expense)−10543−13−23−26−24−101.51.61.3
Income before tax−196−76−143−165−124−196−200−178−129−109
Income tax0.00.10.30.40.30.30.00.00.10.1
Net income including minority interests−196−76−143−165−124−196−200−178−129−110
Net income attributable to shareholders−196−76−143−165−124−196−200−178−129−110
Earnings per share, basic-17.93-9.41r-18.79r-2.02-1.65-2.72-3.22-3.14-2.81-2.92
Earnings per share, diluted-17.93-14.00r-18.79r-2.02-1.65-2.72-3.22-3.14-2.81-2.92
Shares, weighted average (basic)0.00.0r0.0r0.1r7572————
Shares, weighted average (diluted)0.00.0r0.0r0.1r7572r62r0.1r4638
Balance sheet
Cash and cash equivalents616252r135190861291186950
Short-term investments3.246139143381631332107780
Receivables2631274722137.9———
Inventory4.04.73.04.24.12.60.3———
Other current assets9.21212201.59.37.36.41.82.1
Current assets103156r234350276277279335148132
Property, plant and equipment0.10.40.61.11.62.23.03.92.22.8
Right-of-use (leased) assets4.55.94.36.27.99.411———
Long-term investments————————2945
Total assets108164240358305313295341180180
Accounts payable4.05.13.12.81.64.51.04.35.74.8
Current liabilities92926966746046474916
Lease liabilities (non-current)5.76.72.86.19.01113———
Total liabilities4013503773753852632451585118
Retained earnings−1,759−1,563−1,487−1,344−1,179−1,070−873−674−495−366
Shareholders' equity−293−186−136−17−805150183129r162
Total liabilities and equity108164240358305313295341180180
Shares outstanding188.4r115113767465r615042
Cash-flow statement
Depreciation and amortization——————1.00.70.70.7
Share-based compensation14182235302415172022
Cash from operating activities−75−127−93−150−107−160−191−159−74−84
Capital expenditure0−0.10−0.1−0.2−0.1−0.2−2.4−0.1−0.1
Cash from investing activities43957.9−104142−5478−1081725
Cash from financing activities30421.1194741721243167651
Exchange-rate effect on cash0.0−0.0−0.0−0.5−0.00.30.0−0.10.2−0.1
Change in cash−1.99.6−84−61108−42124919r−8.7r
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Karyopharm Therapeutics Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product(total)$115 M79%
  • License and Other Revenue$31 M21%

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Karyopharm Therapeutics Inc. operates: 3 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue. 2 subsidiaries on file.

Karyopharm Therapeutics Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇩🇪 Germany1 subsidiary—
🇮🇱 Israel1 subsidiary—

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Karyopharm Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.3 M
Mr. Paulson
Other top executives, average
$1.7 M
the CEO earned 1.4× this
$100 invested is now
$14
Karyopharm Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mr. Paulson$2.3 M$2.1 M$1.7 M$14
2024Mr. Paulson$2.1 M$1.7 M$1.1 M$20
2023Mr. Paulson$2.6 M$36 K$1.2 M$25

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Karyopharm Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Bankruptcy or receivershipDebt called earlyFiling
  • Debt called earlyFiling

Bankruptcy or receivership 1 · Delisting notice 1 · Debt called early 2 · Directors and officers 6 · Material agreement 6 · New debt 3 · Unregistered share sale 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 9

Karyopharm Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Delisting notice8-K
Bankruptcy or receivershipDebt called earlyMaterial agreementNew debt8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Debt called earlyMaterial agreementUnregistered share sale8-K
Results announced8-K
Directors and officers8-K
Directors and officersShareholder vote8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Results announced8-K
Material agreementNew debt8-K
Directors and officersMaterial agreementNew debtUnregistered share saleResults announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Directors and officers8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

2 private funding rounds before listing

Private share sales · funding history

Private share sales of Karyopharm Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2022$165 MPrivate placement after listing$50 to $250 million33equity, optionsSEC
Jul 2013$19 MNo. 2$10 to $50 million7equitySEC
Apr 2013$21 MNo. 1$10 to $50 million8equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Karyopharm Therapeutics Inc.#

$100 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.

Lobbying, 2025
$100 K
#1,236 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2025
2026 so far
$0
  • Health Issues1 report

Lobbying firms hired in 2025

Sidley Austin LLP $100 K

Karyopharm Therapeutics Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2026 (so far)$0—3
2025$100 K—1
2019$220 K—4
2018$60 K—1

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Karyopharm Therapeutics Inc.,” and “Karyopharm Therapeutics”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Karyopharm Therapeutics Inc.#

4 labor condition applications certified in fiscal 2026 for 4 positions, at a median wage of $189 K a year.

Certified, FY2026
4
#1,237 among companies on value.today
Worker positions
4
Median wage offered
$189 K
a year, full-time
Applications filed
4
Karyopharm Therapeutics Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Manager, Regulatory OperationsRegulatory Affairs Managers2$189 K
Associate Director, Regulatory OperationsRegulatory Affairs Managers1$189 K
Sr Scientist, Analytical ChemistryChemists1$153 K

Where: Newton, MA 4

Karyopharm Therapeutics Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202644$189 K4
FY202588$133 K8
FY202422$125 K2
FY20231313$130 K13
FY20221111$140 K11
FY202155$123 K6
FY20201313$120 K13

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Karyopharm Therapeutics Inc.

FDA drug approvals: Karyopharm Therapeutics Inc.#

1 approved applications held, 1 of them new molecular entities; 0 approvals and 2 new uses in 2020.

Approvals held
1
New molecular entities
1
New uses approved
3
efficacy supplements
Generics
0
1 new drugs, 0 biologics
Karyopharm Therapeutics Inc.: latest FDA approvals
ApprovedDrugKind
2026-04-23Xpovionew useSelinexor · NDA212306 (SUPPL-18)New drug (NDA)
2020-12-18Xpovionew useSelinexor · NDA212306 (SUPPL-5)New drug (NDA)
2020-06-22Xpovionew useSelinexor · NDA212306 (SUPPL-1)New drug (NDA)
2019-07-03Xpovionew moleculeSelinexor · NDA212306New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (KARYOPHARM THERAPS), so they follow acquisitions

How Karyopharm Therapeutics Inc. compares in Biotechnology

  • Market cap$20 M · higher than 17% of 726
  • Revenue$146 M · higher than 73% of 647
  • Net margin-153.3% · higher than 35% of 408
  • Revenue growth0.6% · higher than 46% of 438
  • Price / sales0.1× · lower than 99% of 339

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Karyopharm Therapeutics Inc.🇺🇸$20 M—-153.3%+0.6%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Karyopharm Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Karyopharm Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Karyopharm Therapeutics Inc.? Suggest a correction